The Effect of Clinically Indicated Liraglutide on Pericoronary Adipose Tissue in Type 2 Diabetic Patients.
Journal
Cardiovascular therapeutics
ISSN: 1755-5922
Titre abrégé: Cardiovasc Ther
Pays: England
ID NLM: 101319630
Informations de publication
Date de publication:
2023
2023
Historique:
received:
04
10
2022
revised:
18
12
2022
accepted:
21
12
2022
entrez:
30
1
2023
pubmed:
31
1
2023
medline:
1
2
2023
Statut:
epublish
Résumé
Vascular inflammation can be detected in the pericoronary adipose tissue (PCAT) by coronary computed tomography angiography (CCTA) attenuation. Treatment with liraglutide is associated with anti-inflammatory effects and reduces cardiovascular risk in diabetic patients. This study is aimed at examining the effect of clinically indicated liraglutide on PCAT attenuation. Asymptomatic patients with type 2 diabetes mellitus (T2DM) and without known ischemic heart disease underwent clinical examination, blood analysis, and CCTA. The main coronary arteries were outlined and PCAT attenuation was measured on the proximal 40 mm. Patients treated with liraglutide on a clinical indication were compared to patients not receiving liraglutide. The study included 190 patients; 53 (28%) received liraglutide (Lira+) and 137 (72%) did not (Lira-). There were no significant differences in PCAT attenuation between the two groups in either artery. However, PCAT attenuation measured around the left anterior descending artery (LAD) was lower in the Lira+ group after adjustment for age, sex, body mass index, and T2DM duration (
Identifiants
pubmed: 36714196
doi: 10.1155/2023/5126825
pmc: PMC9867582
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5126825Informations de copyright
Copyright © 2023 Irmelin I. A. Biesenbach et al.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest regarding the publication of this paper. The first author did not receive any salary and the last author is employed at the University of Southern Denmark.
Références
Cardiovasc Diabetol. 2022 Mar 18;21(1):44
pubmed: 35303857
Diabetologia. 2014 Apr;57(4):781-4
pubmed: 24362727
J Am Coll Cardiol. 2005 Jul 19;46(2):261-5
pubmed: 16022952
Diabetes. 2015 Apr;64(4):1395-406
pubmed: 25325735
Lancet. 2018 Sep 15;392(10151):929-939
pubmed: 30170852
Am J Cardiol. 2004 Jan 1;93(1):73-5
pubmed: 14697470
Diabetes Res Clin Pract. 2019 Nov;157:107843
pubmed: 31518657
Int J Cardiovasc Imaging. 2013 Jun;29(5):1177-90
pubmed: 23417447
Biomed Pharmacother. 2020 Jul;127:110218
pubmed: 32559849
PLoS One. 2014 May 16;9(5):e97554
pubmed: 24835252
Eur Heart J. 2020 Feb 1;41(6):748-758
pubmed: 31317172
IUBMB Life. 2019 Sep;71(9):1347-1354
pubmed: 30969479
N Engl J Med. 2019 Dec 26;381(26):2497-2505
pubmed: 31733140
Heart. 2002 Mar;87(3):201-4
pubmed: 11847151
Diabetes Care. 2011 Jan;34 Suppl 1:S11-61
pubmed: 21193625
Atherosclerosis. 2012 Apr;221(2):375-82
pubmed: 22284365
Cardiovasc Diabetol. 2018 Oct 10;17(1):134
pubmed: 30305178
Mol Metab. 2021 Dec;54:101337
pubmed: 34500107
J Cardiovasc Comput Tomogr. 2022 Jul-Aug;16(4):327-335
pubmed: 35140051
Eur Rev Med Pharmacol Sci. 2021 Oct;25(19):6013-6024
pubmed: 34661261
Cardiovasc Diabetol. 2019 Apr 23;18(1):51
pubmed: 31014330
Diabetes Res Clin Pract. 2020 Apr;162:108086
pubmed: 32068099
Diabetes Care. 1998 Jul;21(7):1167-72
pubmed: 9653614
JACC Cardiovasc Imaging. 2010 Feb;3(2):168-75
pubmed: 20159644
Eur Heart J Cardiovasc Imaging. 2019 Jun 1;20(6):636-643
pubmed: 30789223
Diabetes Care. 2016 Jan;39 Suppl 1:S60-71
pubmed: 26696684
Biosci Rep. 2018 Feb 12;:
pubmed: 29440457
N Engl J Med. 1999 Jan 14;340(2):115-26
pubmed: 9887164
Front Endocrinol (Lausanne). 2021 Nov 30;12:790405
pubmed: 34917038
JAMA. 2004 Nov 24;292(20):2495-9
pubmed: 15562129
Diabetes Res Clin Pract. 2015 Nov;110(2):224-8
pubmed: 26376464
Clin Radiol. 2013 Oct;68(10):1054-8
pubmed: 23809270
J Int Med Res. 2021 Feb;49(2):300060521992981
pubmed: 33641439
Diabetologia. 2022 Dec;65(12):2000-2010
pubmed: 35925319
JAMA Cardiol. 2018 Sep 1;3(9):858-863
pubmed: 30027285
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785
pubmed: 31422062
Nat Rev Endocrinol. 2012 Dec;8(12):728-42
pubmed: 22945360
Cardiovasc Diabetol. 2021 Aug 9;20(1):164
pubmed: 34372839
Curr Pharm Des. 2020;26(22):2565-2573
pubmed: 32053065
Eur Heart J Cardiovasc Imaging. 2021 Feb 22;22(3):298-306
pubmed: 33106867
J Clin Endocrinol Metab. 2001 May;86(5):1930-5
pubmed: 11344187
Mediators Inflamm. 2021 Mar 27;2021:5568159
pubmed: 33854404
N Engl J Med. 2016 Jul 28;375(4):311-22
pubmed: 27295427
Biomedicines. 2021 Jul 28;9(8):
pubmed: 34440108
N Engl J Med. 2005 Apr 21;352(16):1685-95
pubmed: 15843671
Int Immunopharmacol. 2021 Oct;99:107926
pubmed: 34233231
Circ Cardiovasc Imaging. 2021 Jul;14(7):e012174
pubmed: 34187185
Nutr Metab Cardiovasc Dis. 2021 Mar 10;31(3):699-704
pubmed: 33549430
BMC Cardiovasc Disord. 2021 Jun 2;21(1):269
pubmed: 34078282
Sci Transl Med. 2017 Jul 12;9(398):
pubmed: 28701474
Horm Metab Res. 2017 Aug;49(8):625-630
pubmed: 28514806
Int J Prev Med. 2014 Aug;5(8):927-46
pubmed: 25489440
J Cardiol. 2015 Mar;65(3):230-6
pubmed: 24994019
Diabetes. 2004 May;53(5):1187-94
pubmed: 15111485
Clin Pharmacokinet. 2016 Jun;55(6):657-72
pubmed: 26597252
J Cardiovasc Comput Tomogr. 2019 Sep - Oct;13(5):288-296
pubmed: 30952610